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Abstract
Background: Lung cancer is the leading cause of cancer-related deaths among males and the second
among females. The importance of lung cancer is a major public health problem and there is a need to find
effective therapies for its management. Erlotinib has been approved to treat non-small-cell lung cancer. The
author's experience in the use of erlonitib in lung cancer patients in Mexico City is described below.
Methods: The series includes 17 consecutive patients treated for advanced lung cancer. All patients had
measurable disease. Treatment continues until disease progression or significant toxicity occurs. Among
patients, adenocarcinoma was the most common tumor histology, followed by bronchioloalveolar tumor,
and epidermoid carcinoma. Nine patients received erlotinib as first-line therapy. Of the remaining 8
patients, 4 had undergone surgery, 2 had received chemotherapy, and 2 had received combined
chemotherapy and radiotherapy.
Results: Four patients achieved complete remission of the disease, and 7 showed partial response. Five
subjects experienced disease progression, and one patient showed stable disease. The most significant cases
were two non-smokers women with bronchioloalveolar cancer, who remain in complete remission after
erlotinib treatment. A non-smoker male patient with adenocarcinoma histology, who rejected
chemotherapy and radiotherapy, it remains in complete remission after 15 months of treatment. A man
with epidermoid carcinoma, with previous surgery and treated with chemotherapy and radiotherapy, with
tumor recurrence, showed a complete 15-month remission with erlotinib. It was observed clinical response
due to treatment with erlotinib despite the tumor histopathology, but therapeutic response was better in
patients without smoking history. The most common adverse events associated with erlotinib therapy were
dermatologic. After discontinuing treatment for a short period, patients were again given erlotinib without
experiencing toxic effects. Hepatotoxic side effects associated to erlotinib were mild and reversible.
Conclusion: Data from this small series of patients support findings reported in the literature. Female non-
smokers showed the best therapeutic response to erlotinib treatment. Erlotinib could be considered as a
first-line therapeutic option in elderly patients with locally advanced or metastatic lung cancer, or in women
with adenocarcinoma.
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Background
Lung cancer is the most common cause of death from can-
cer in both men and women worldwide [1]. Among males
it is the leading cause of cancer-related deaths, while
among females it is second only to breast cancer [2]. In
Mexico, crude mortality due to lung cancer in 1979 was
5.01 per 105 people [3]. Data from a recently published
study place emphasis on lung cancer burden in Mexico
[4]. From 1998 to 2004 approximately 400,000 deaths
from cancer were reported in that country, with lung can-
cer accounting for 11.5% of them. Mean mortality rate
from this neoplasm was 8.9 per 105 people among males
and 4.1 per 105 people among females. The highest over-
all mortality rates from lung cancer were noted in the
northern regions of the country, where the most industri-
alized states are located. However, if women are consid-
ered individually, the highest rates were found in the
central states. Days of life potentially lost due to lung can-
cer were nearly 260,000 among men and approximately
133,000 among women. These figures underscore the
importance of lung cancer as a major public health prob-
lem and the need to find effective therapies for its man-
agement.
Erlotinib is a new potent inhibitor of the epidermal
growth factor receptor (HER1/EGFR) which has been
approved to treat non-small-cell lung cancer (NSCLC).
The author's experience in the use of erlonitib in lung can-
cer patients in Mexico City is described below.
Methods
Population
The series includes 17 consecutive patients treated for
advanced lung cancer from November 2005 to November
2007. Patients' median age is 64 years (range 47–82). All
patients had measurable disease, and 11 of them had no
smoking history. Nine patients were female. The first 10
patients of the series were enrolled according to the proto-
col for the Expanded Access Program of TRUST (TaRceva
lUng cancer Survival Treatment), developed in 52 coun-
tries after results of the phase III trial referred to as BR.21
were available [5,6]. The following 7 patients were
included in this series out of protocol and were selected by
sex and tumor histology. Median follow-up for all
patients enrolled in the series was 9 months.
The TRUST study is a phase IV multicenter open-label
non-randomized trial in patients with advanced nonre-
sectable stage IIIB/IV NSCLC after failure of prior standard
chemotherapy or radiotherapy regimen, or who are not
candidates for cytotoxic chemotherapy, or refuse such
therapy [6]. Performance status (PS) of enrolled patients
could range from 0 to 3 as measured by ECOG score, and
liver, renal and hematological function had to be ade-
quate prior onset of treatment. The protocol is currently
active although enrollment of patients is closed. Treat-
ment continues until disease progression or significant
toxicity occurs. Dose may be reduced in 50 mg decrements
in the event of severe toxic effects. Until March 2007 data
from 5908 patients were available, according to an inten-
tion-to-treat analysis.
Histopathologic and clinical features: previous therapy
In this series patients were not randomly assigned; there
was some degree of selection. Adenocarcinoma was the
most common tumor histology (8 patients; 5 women, 3
men), followed by bronchioloalveolar tumor (6 patients;
4 women, 2 men), and epidermoid carcinoma (3 male
patients). The greater number of women included in the
series reflects selection by histopathological type of
tumor. Clinical stage was III in 14 patients and IV in 3
patients.
Nine patients received erlotinib as first-line therapy (the 7
out-of-protocol patients and 2 patients enrolled according
to protocol who refused standard chemotherapy as treat-
ment). Of the remaining 8 patients, 4 had undergone sur-
gery, 2 had received chemotherapy, and 2 had received
combined chemotherapy and radiotherapy.
Results
Four patients (23.5%) achieved complete remission of the
disease, and 7 (41%) showed partial response. Five sub-
jects experienced disease progression (29.4%), and one
patient showed stable disease. Overall clinical benefit was
70.5%, and median duration of partial response was 6
months. It should be noted that these patients had some
degree of selection and that response might not be so
favorable in a non-selected population [7]. However, pre-
liminary analysis of results from the TRUST trial shows
that disease control rate (complete or partial response, or
stable disease for at least 4 weeks) was 73% with erlotinib
as first-line, 67% as second-line, and 66% as third-line
therapy [6]. Therefore, the results in this series are similar
to those of the overall population included in the proto-
col. These data could indicate that in patients selected
according to tumor histology, smoking history and gen-
der, among other factors, administration of erlotinib
would provide the highest benefit, as suggested by some
authors [7].
Among the most significant cases included in this series,
two merit a particular discussion: 2 women aged 52 and
73 years, non-smokers, with bronchioloalveolar cancer,
who remain in complete remission after 7 and 11 months
of treatment, respectively. It should be noted that remis-
sion was observed during the first month of treatment
with erlotinib. Monthly clinical as well as radiological and
laboratory check-ups of enrolled patients allowed this
finding [5,6]. Out-of-protocol patients in this seriesBMC Proceedings 2008, 2(Suppl 2):S2 http://www.biomedcentral.com/1753-6561/2/S2/S2
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underwent similar check-ups as those required for the
TRUST trial. In the two patients mentioned above, evi-
dence of tumor activity was no longer observed within
one month after treatment onset.
One of the cases included in this experience was an 80
year-old non-smoker male patient, with adenocarcinoma
histology, who rejected chemotherapy and radiotherapy,
and who was not a candidate for surgery due to advanced
stage disease, and was therefore included in the TRUST
protocol. The patient remains in complete remission after
15 months of treatment.
Another patient, a 73 year old man with epidermoid car-
cinoma, with previous surgery and treated with chemo-
therapy and radiotherapy, with tumor recurrence in the
chest and neck on the opposite side of the primary tumor,
showed a complete 15-month remission with erlotinib.
It should be noted that in this experience 5 patients were
> 70 years old, and 3 of them showed complete remission.
Therapeutic response according to tumor histopathology 
and smoking history
The evaluation of the relationship between tumor his-
topathology and therapeutic response to erlotinib in this
series of patients, shows that 4 of the 8 patients with ade-
nocarcinoma had positive therapeutic response. Five of
the 6 patients with bronchioloalveolar carcinoma showed
therapeutic response, and 1, stable disease. Clinical
response was also observed in 2 of the 3 patients with epi-
dermoid carcinoma.
As regards smoking status, therapeutic response was better
in patients without smoking history (8 of the 11 patients
responded and 1 remained with stable disease, compared
to 3 responders among 6 smokers).
Despite the limited number of patients, these results are
consistent with data from published literature [7].
Adverse effects
A crucial issue in this series was determining the type and
frequency of adverse effects associated with erlotinib ther-
apy. The most common adverse events were dermato-
logic. Grade 4 rash was found in 2 patients (12%), grade
3 in 9 patients (53%), and grade 2 in 6 patients (35%).
Data from TRUST protocol available to date show that
skin rash is a highly common adverse effect, affecting 70%
of patients. However, in most of them rash was grade 1
and 2 (58%) [6].
In 10 of the 17 patients included in the series, dose was
reduced to 100 mg due to dermatologic side effects. In
these cases, dose reduction did not appear to significantly
affect therapeutic response. Data from the TRUST trial
show that only 13% of patients required reduction of the
dose due to adverse effects (mainly rash and/or diarrhea),
and 6% experienced an erlotinib-related adverse effect
leading to treatment withdrawal [6].
When looking at hepatic adverse effects, laboratory data
showed grade 3 of toxicity in 1 patient, and grade 2 of tox-
icity in 2 patients. Toxic effects were detected through
abnormal liver function tests in all cases, and no clinical
effects were observed. After discontinuing treatment for a
short period, liver function markers returned to normal.
Patients were again given erlotinib at the initial dose with-
out experiencing such toxic effects again. These data are
consistent with those reported in previous studies show-
ing that hepatotoxic effects are uncommon, and usually
mild and reversible [8,9].
Fatigue occurred in 47% of patients. It is difficult to deter-
mine whether this symptom is related to therapy, since it
may be another manifestation of the underlying disease.
The other frequent treatment-related adverse effect of erlo-
tinib was diarrhea, which in some studies has occurred in
up to 72% of patients [8]. In this series of patients, how-
ever, this condition was not so frequent, since only 2
patients developed grade 2 diarrhea (11%), which
resolved with symptomatic treatment. This figure is
slightly higher than the one found in the TRUST trial,
where only 1% of enrolled patients experienced diarrhea
[6]. A possible explanation for the data from this series of
patients could be a reduction in the dose of erlotinib,
already recommended. Still, patients did not develop
diarrhea either when given the 150 mg dose, rather they
showed dermatologic effects.
Conclusion
In this experience with 17 patients, 5 of them were older
than 70 years of age and 3 achieved complete remission.
Data from this small series of patients support findings
reported in the literature regarding adenocarcinoma his-
tology, which responds better to erlotinib than other his-
tologic subtypes of NSCLC. Moreover, female non-
smokers showed the best therapeutic response. Neverthe-
less, male patients with epidermoid histology may also be
benefited.
Despite erlotinib dose reduction, disease-free period was
considered to be relatively long.
In addition to its already established indications as sec-
ond- and third-line therapy, erlotinib could be considered
as a first-line therapeutic option in elderly patients withPublish with BioMed Central    and   every 
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locally advanced or metastatic lung cancer, or in women
with adenocarcinoma.
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